First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
J Greenhalgh, A Boland, V Bates… - COCHRANE …, 2021 - livrepository.liverpool.ac.uk
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
[引用][C] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
J Greenhalgh, K Dwan, A Boland, V Bates… - Cochrane Database of …, 2016 - cir.nii.ac.jp
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive
non-squamous non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …
non-squamous non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報 …
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, K Dwan, A Boland… - Cochrane Database …, 2016 - cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10 …
lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10 …
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
J Greenhalgh, A Boland, V Bates… - The Cochrane …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
[HTML][HTML] First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - archive.lstmed.ac.uk
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
[HTML][HTML] First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - The Cochrane …, 2021 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
J Greenhalgh, A Boland, V Bates, F Vecchio… - The Cochrane …, 2021 - europepmc.org
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
J Greenhalgh, K Dwan, A Boland, V Bates… - The Cochrane …, 2016 - europepmc.org
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell
lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10 …
lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10 …
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
J Greenhalgh, K Dwan, A Boland… - The Cochrane …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell
lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10 …
lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10 …